<p>PROCEPT BioRobotics Corporation（納斯達克股票代碼：PRCT - 獲取免費報告）的股票在週二上漲了 7.4%。該公司的股價最高達到 28.17 美元，最後交易價格為 28.4110 美元。在午盤交易中，約有 588,266 股成交，較日均成交量 1,533,480 股下降了 62%。該股票此前收盤價為 26.45 美元。</p>
<p>獲取 <strong>PROCEPT BioRobotics</strong> 的最新動態：</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>3 只被低估的機器人股票有望獲得巨大收益</li>
</ul>
<p>幾家研究公司對 PRCT 進行了評估。Oppenheimer 在 2 月 26 日的研究報告中重新發布了對 PROCEPT BioRobotics 股票的 “市場表現” 評級。Robert W. Baird 在 3 月 6 日的研究報告中開始覆蓋 PROCEPT BioRobotics。他們對該股票給予了 “中性” 評級，目標價為 30.00 美元。美國銀行在 2 月 26 日的研究報告中將 PROCEPT BioRobotics 的評級從 “中性” 下調至 “表現不佳”，並將目標價從 38.00 美元下調至 20.00 美元。Leerink Partners 在 2 月 26 日的報告中將 PROCEPT BioRobotics 的目標價從 55.00 美元下調至 30.00 美元，並給予該公司 “跑贏大盤” 的評級。最後，Piper Sandler 在 4 月 30 日的研究報告中重申了 “增持” 評級，並將目標價從 28.00 美元上調至 35.00 美元。八位研究分析師對該股票給予了買入評級，四位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，PROCEPT BioRobotics 的共識評級為 “持有”，共識目標價為 41.45 美元。</p>
<p><strong>查看我們關於 PROCEPT BioRobotics 的最新報告</strong></p>
<h2>PROCEPT BioRobotics 股票上漲 7.7%</h2>
<ul>
<li>PROCEPT BioRobotics 是外科機器人領域的下一個大事件嗎？</li>
</ul>
<p>該公司的市值為 16.2 億美元，市盈率為-15.66，貝塔值為 0.83。公司的債務與股本比率為 0.15，流動比率為 6.73，速動比率為 5.51。該公司的 50 日移動平均線為 25.06 美元，200 日移動平均線為 29.17 美元。</p>
<p>PROCEPT BioRobotics（納斯達克股票代碼：PRCT - 獲取免費報告）最近在 4 月 29 日公佈了季度財報。該公司報告季度每股收益為（0.56 美元），低於市場共識預期的（0.55 美元）0.01 美元。PROCEPT BioRobotics 的淨利潤率為-31.82%，股本回報率為-27.70%。該公司在本季度的收入為 8313 萬美元，而分析師的預期為 8052 萬美元。在去年同期，該公司每股收益為（0.45 美元）。PROCEPT BioRobotics 的收入同比增長了 20.1%。賣方分析師預計 PROCEPT BioRobotics Corporation 在本財年的每股收益將為-1.53 美元。</p>
<h2>PROCEPT BioRobotics 的內部交易</h2>
<ul>
<li>為什麼 Intuitive Surgical 的股票在醫療領域佔據主導地位</li>
</ul>
<p>在其他新聞中，執行副總裁 Alaleh Nouri 在 3 月 19 日的交易中出售了 5,363 股 PROCEPT BioRobotics 的股票。該股票以平均價格 25.96 美元出售，總價值為 139,223.48 美元。出售後，該執行副總裁直接持有公司 105,354 股股票，價值約為 2,734,989.84 美元。此次交易使其持股減少了 4.84%。該出售在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。此外，董事 Antal Rohit Desai 在 3 月 9 日的交易中購買了 98,699 股 PROCEPT BioRobotics 的股票。該股票以每股平均 24.55 美元的價格購買，總交易額為 2,423,060.45 美元。完成收購後，該董事直接持有公司 426,262 股股票，價值約為 10,464,732.10 美元。此次交易使其持股增加了 30.13%。有關此次購買的更多細節可在官方 SEC 披露中找到。在過去三個月中，內部人士購買了 426,262 股公司股票，價值為 10,483,091 美元，並出售了 23,229 股，價值為 573,466 美元。內部人士持有公司 17.40% 的股份。</p>
<h2>機構投資者對 PROCEPT BioRobotics 的看法</h2>
<p>幾家大型投資者最近增加或減少了對該股票的持股。Prosight Management LP 在第四季度將其在 PROCEPT BioRobotics 的持股增加了 1,692.4%。Prosight Management LP 現在持有 138 萬股公司股票，價值 4341.5 萬美元，此前在上個季度又購買了 1,303,009 股。Alliancebernstein L.P.在第三季度將其在 PROCEPT BioRobotics 的持股增加了 58.6%。Alliancebernstein L.P.現在持有 3419784 股公司股票，價值 1.22052 億美元，此前在上個季度又購買了 1,262,928 股。T. Rowe Price Investment Management Inc.在第四季度將其在 PROCEPT BioRobotics 的持股增加了 59.4%。T. Rowe Price Investment Management Inc.現在持有 3271408 股公司股票，價值 1.02919 億美元，此前在上個季度又購買了 1,218,815 股。ArrowMark Colorado Holdings LLC 在第三季度將其在 PROCEPT BioRobotics 的持股增加了 229.7%。ArrowMark Colorado Holdings LLC 現在持有 1128288 股公司股票，價值 4026.9 萬美元，此前在上個季度又購買了 786,094 股。最後，Mackenzie Financial Corp 在第三季度將其在 PROCEPT BioRobotics 的持股增加了 105.2%。Mackenzie Financial Corp 現在持有 1454434 股公司股票，價值 5190.9 萬美元，此前在上個季度又購買了 745,778 股。89.46% 的股票由機構投資者持有。</p>
<h2>PROCEPT BioRobotics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>PROCEPT BioRobotics, Inc 是一家醫療設備公司，專注於開發和商業化用於治療良性前列腺增生（BPH）的機器人系統。該公司的技術利用精密機器人和實時成像進行微創手術，旨在減少患者恢復時間，並改善與傳統外科方法相比的臨牀結果。</p>
<p>該公司的旗艦產品 AquaBeam 機器人系統使用高速水射流選擇性去除前列腺組織，同時保護周圍健康結構。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們認為比 PROCEPT BioRobotics 更好的股票</li>
<li>AST SpaceMobile 因銀河第一季度業績不佳暴跌：垂直整合能拯救這家 SpaceX 競爭對手嗎？</li>
<li>Axon 在財報發佈後大漲，但仍比高點下跌超過 50%</li>
<li>可能重新定義蘋果夏季反彈的事件</li>
<li>Hims &amp; Hers 股票在第一季度業績不佳後暴跌：GLP-1 的轉變足以推動復甦嗎？</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 PROCEPT BioRobotics 嗎？</h2>
<p>在考慮 PROCEPT BioRobotics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 PROCEPT BioRobotics 並不在名單上。</p>
<p>雖然 PROCEPT BioRobotics 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PRCT

2 倍做多納斯達克生物技術 ETF - ProShares

標普生物技術 3 倍做多 - Direxion

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

醫藥突破 ETF - ALPS

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>PROCEPT BioRobotics（納斯達克代碼：PRCT）的股價在週二上漲了 7.4%，達到 28.41 美元，交易量為 588,266 股。分析師對該股票的評級不一，Oppenheimer 維持 “市場表現” 評級，而美國銀行則將其下調至 “表現不佳”，目標價為 20 美元。該公司報告的收入同比增長 20.1%，但未能達到每股收益預期。內部交易活動包括顯著的買入和賣出。該股票的共識評級為 “持有”，目標價為 41.45 美元</p>

<p>Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) rose 7.4% on Tuesday . The company traded as high as $28.17 and last traded at $28.4110. Approximately 588,266 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 1,533,480 shares. The stock had previously closed at $26.45.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics Corporation（納斯達克股票代碼：PRCT - 獲取免費報告）的股票在週二上漲了 7.4%。該公司的股價最高達到 28.17 美元，最後交易價格為 28.4110 美元。在午盤交易中，約有 588,266 股成交，較日均成交量 1,533,480 股下降了 62%。該股票此前收盤價為 26.45 美元。</p>
</div><p>Get <strong>PROCEPT BioRobotics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>PROCEPT BioRobotics</strong> 的最新動態：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>3 Underrated Robotics Stocks Poised for Huge Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只被低估的機器人股票有望獲得巨大收益</li>
</ul>
</div><p>Several research firms have weighed in on PRCT. Oppenheimer reissued a &#34;market perform&#34; rating on shares of PROCEPT BioRobotics in a research report on Thursday, February 26th. Robert W. Baird initiated coverage on PROCEPT BioRobotics in a research report on Friday, March 6th. They issued a &#34;neutral&#34; rating and a $30.00 price objective on the stock. Bank of America lowered PROCEPT BioRobotics from a &#34;neutral&#34; rating to an &#34;underperform&#34; rating and decreased their target price for the stock from $38.00 to $20.00 in a research note on Thursday, February 26th. Leerink Partners cut their price objective on PROCEPT BioRobotics from $55.00 to $30.00 and set an &#34;outperform&#34; rating for the company in a report on Thursday, February 26th. Finally, Piper Sandler restated an &#34;overweight&#34; rating and issued a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a research note on Thursday, April 30th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, PROCEPT BioRobotics has a consensus rating of &#34;Hold&#34; and a consensus price target of $41.45.</p>
<div class="lb-trans"><p>幾家研究公司對 PRCT 進行了評估。Oppenheimer 在 2 月 26 日的研究報告中重新發布了對 PROCEPT BioRobotics 股票的 “市場表現” 評級。Robert W. Baird 在 3 月 6 日的研究報告中開始覆蓋 PROCEPT BioRobotics。他們對該股票給予了 “中性” 評級，目標價為 30.00 美元。美國銀行在 2 月 26 日的研究報告中將 PROCEPT BioRobotics 的評級從 “中性” 下調至 “表現不佳”，並將目標價從 38.00 美元下調至 20.00 美元。Leerink Partners 在 2 月 26 日的報告中將 PROCEPT BioRobotics 的目標價從 55.00 美元下調至 30.00 美元，並給予該公司 “跑贏大盤” 的評級。最後，Piper Sandler 在 4 月 30 日的研究報告中重申了 “增持” 評級，並將目標價從 28.00 美元上調至 35.00 美元。八位研究分析師對該股票給予了買入評級，四位給予了持有評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，PROCEPT BioRobotics 的共識評級為 “持有”，共識目標價為 41.45 美元。</p>
</div><p><strong>Check Out Our Latest Report on PROCEPT BioRobotics</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 PROCEPT BioRobotics 的最新報告</strong></p>
</div><h2>PROCEPT BioRobotics Stock Up 7.7%</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 股票上漲 7.7%</h2>
</div><ul>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
</ul>
<div class="lb-trans"><ul>
<li>PROCEPT BioRobotics 是外科機器人領域的下一個大事件嗎？</li>
</ul>
</div><p>The company has a market capitalization of $1.62 billion, a PE ratio of -15.66 and a beta of 0.83. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.73 and a quick ratio of 5.51. The company has a 50-day moving average of $25.06 and a two-hundred day moving average of $29.17.</p>
<div class="lb-trans"><p>該公司的市值為 16.2 億美元，市盈率為-15.66，貝塔值為 0.83。公司的債務與股本比率為 0.15，流動比率為 6.73，速動比率為 5.51。該公司的 50 日移動平均線為 25.06 美元，200 日移動平均線為 29.17 美元。</p>
</div><p>PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative net margin of 31.82% and a negative return on equity of 27.70%. The business had revenue of $83.13 million during the quarter, compared to analysts' expectations of $80.52 million. During the same quarter in the previous year, the firm earned ($0.45) earnings per share. PROCEPT BioRobotics's revenue was up 20.1% on a year-over-year basis. Sell-side analysts anticipate that PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics（納斯達克股票代碼：PRCT - 獲取免費報告）最近在 4 月 29 日公佈了季度財報。該公司報告季度每股收益為（0.56 美元），低於市場共識預期的（0.55 美元）0.01 美元。PROCEPT BioRobotics 的淨利潤率為-31.82%，股本回報率為-27.70%。該公司在本季度的收入為 8313 萬美元，而分析師的預期為 8052 萬美元。在去年同期，該公司每股收益為（0.45 美元）。PROCEPT BioRobotics 的收入同比增長了 20.1%。賣方分析師預計 PROCEPT BioRobotics Corporation 在本財年的每股收益將為-1.53 美元。</p>
</div><h2>Insider Transactions at PROCEPT BioRobotics</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 的內部交易</h2>
</div><ul>
<li>Why Intuitive Surgical Stock is Dominating the Medical Sector</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼 Intuitive Surgical 的股票在醫療領域佔據主導地位</li>
</ul>
</div><p>In other news, EVP Alaleh Nouri sold 5,363 shares of PROCEPT BioRobotics stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $25.96, for a total value of $139,223.48. Following the sale, the executive vice president directly owned 105,354 shares of the company's stock, valued at approximately $2,734,989.84. The trade was a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Antal Rohit Desai bought 98,699 shares of PROCEPT BioRobotics stock in a transaction dated Monday, March 9th. The stock was purchased at an average cost of $24.55 per share, for a total transaction of $2,423,060.45. Following the completion of the acquisition, the director directly owned 426,262 shares of the company's stock, valued at approximately $10,464,732.10. The trade was a 30.13% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have bought 426,262 shares of company stock valued at $10,483,091 and have sold 23,229 shares valued at $573,466. Insiders own 17.40% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，執行副總裁 Alaleh Nouri 在 3 月 19 日的交易中出售了 5,363 股 PROCEPT BioRobotics 的股票。該股票以平均價格 25.96 美元出售，總價值為 139,223.48 美元。出售後，該執行副總裁直接持有公司 105,354 股股票，價值約為 2,734,989.84 美元。此次交易使其持股減少了 4.84%。該出售在向 SEC 提交的文件中披露，相關文件可通過此鏈接訪問。此外，董事 Antal Rohit Desai 在 3 月 9 日的交易中購買了 98,699 股 PROCEPT BioRobotics 的股票。該股票以每股平均 24.55 美元的價格購買，總交易額為 2,423,060.45 美元。完成收購後，該董事直接持有公司 426,262 股股票，價值約為 10,464,732.10 美元。此次交易使其持股增加了 30.13%。有關此次購買的更多細節可在官方 SEC 披露中找到。在過去三個月中，內部人士購買了 426,262 股公司股票，價值為 10,483,091 美元，並出售了 23,229 股，價值為 573,466 美元。內部人士持有公司 17.40% 的股份。</p>
</div><h2>Institutional Investors Weigh In On PROCEPT BioRobotics</h2>
<div class="lb-trans"><h2>機構投資者對 PROCEPT BioRobotics 的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the stock. Prosight Management LP grew its stake in shares of PROCEPT BioRobotics by 1,692.4% during the fourth quarter. Prosight Management LP now owns 1,380,000 shares of the company's stock valued at $43,415,000 after buying an additional 1,303,009 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of PROCEPT BioRobotics by 58.6% during the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company's stock valued at $122,052,000 after buying an additional 1,262,928 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in shares of PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company's stock valued at $102,919,000 after buying an additional 1,218,815 shares during the last quarter. ArrowMark Colorado Holdings LLC grew its stake in shares of PROCEPT BioRobotics by 229.7% during the third quarter. ArrowMark Colorado Holdings LLC now owns 1,128,288 shares of the company's stock valued at $40,269,000 after buying an additional 786,094 shares during the last quarter. Finally, Mackenzie Financial Corp grew its stake in shares of PROCEPT BioRobotics by 105.2% during the third quarter. Mackenzie Financial Corp now owns 1,454,434 shares of the company's stock valued at $51,909,000 after buying an additional 745,778 shares during the last quarter. 89.46% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>幾家大型投資者最近增加或減少了對該股票的持股。Prosight Management LP 在第四季度將其在 PROCEPT BioRobotics 的持股增加了 1,692.4%。Prosight Management LP 現在持有 138 萬股公司股票，價值 4341.5 萬美元，此前在上個季度又購買了 1,303,009 股。Alliancebernstein L.P.在第三季度將其在 PROCEPT BioRobotics 的持股增加了 58.6%。Alliancebernstein L.P.現在持有 3419784 股公司股票，價值 1.22052 億美元，此前在上個季度又購買了 1,262,928 股。T. Rowe Price Investment Management Inc.在第四季度將其在 PROCEPT BioRobotics 的持股增加了 59.4%。T. Rowe Price Investment Management Inc.現在持有 3271408 股公司股票，價值 1.02919 億美元，此前在上個季度又購買了 1,218,815 股。ArrowMark Colorado Holdings LLC 在第三季度將其在 PROCEPT BioRobotics 的持股增加了 229.7%。ArrowMark Colorado Holdings LLC 現在持有 1128288 股公司股票，價值 4026.9 萬美元，此前在上個季度又購買了 786,094 股。最後，Mackenzie Financial Corp 在第三季度將其在 PROCEPT BioRobotics 的持股增加了 105.2%。Mackenzie Financial Corp 現在持有 1454434 股公司股票，價值 5190.9 萬美元，此前在上個季度又購買了 745,778 股。89.46% 的股票由機構投資者持有。</p>
</div><h2>PROCEPT BioRobotics Company Profile</h2>
<div class="lb-trans"><h2>PROCEPT BioRobotics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.</p>
<div class="lb-trans"><p>PROCEPT BioRobotics, Inc 是一家醫療設備公司，專注於開發和商業化用於治療良性前列腺增生（BPH）的機器人系統。該公司的技術利用精密機器人和實時成像進行微創手術，旨在減少患者恢復時間，並改善與傳統外科方法相比的臨牀結果。</p>
</div><p>The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.</p>
<div class="lb-trans"><p>該公司的旗艦產品 AquaBeam 機器人系統使用高速水射流選擇性去除前列腺組織，同時保護周圍健康結構。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than PROCEPT BioRobotics</li>
<li>AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?</li>
<li>Axon Surged After Earnings and Is Still Down Over 50% From Highs</li>
<li>The Event That Could Redefine Apple’s Summer Rally</li>
<li>Hims &amp; Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 PROCEPT BioRobotics 更好的股票</li>
<li>AST SpaceMobile 因銀河第一季度業績不佳暴跌：垂直整合能拯救這家 SpaceX 競爭對手嗎？</li>
<li>Axon 在財報發佈後大漲，但仍比高點下跌超過 50%</li>
<li>可能重新定義蘋果夏季反彈的事件</li>
<li>Hims &amp; Hers 股票在第一季度業績不佳後暴跌：GLP-1 的轉變足以推動復甦嗎？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in PROCEPT BioRobotics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 PROCEPT BioRobotics 嗎？</h2>
</div><p>Before you consider PROCEPT BioRobotics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 PROCEPT BioRobotics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 PROCEPT BioRobotics 並不在名單上。</p>
</div><p>While PROCEPT BioRobotics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 PROCEPT BioRobotics 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

PROCEPT BioRobotics（NASDAQ:PRCT）股價上漲 7.4% - 是否值得購買？